A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment.

Trial Profile

A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs TL 118 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Tiltan Pharma
  • Most Recent Events

    • 04 Feb 2016 Planned End Date changed from 1 May 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 04 Feb 2016 Planned primary completion date changed from 1 May 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
    • 04 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top